Report workspace

Add to folder
NCT05533996UNKNOWNanonymous

Body Fat Index as a Novel Sonographic Tool to Predict High Risk Pregnancy (BFiORS Trial)

Sponsor

Source record

Assiut University

Phase

Source record

Not Applicable

Modality

AI-normalized

RNA therapy

Target

AI-normalized

Body Fat Index (BFI) as a predictive tool for gestational diabetes mellitus (GDM) and other pregnancy-related complications.

Indication / condition

AI-normalized

Gestational Diabetes

Intervention

Source record

ultrasound

Source & freshness

Source record

NCT ID

NCT05533996

Original source

ClinicalTrials.gov

Source last updated

Oct 13, 2022

Ingested at

Jun 17, 2026

Internal sync

Jun 17, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT05533996

Title

Body Fat Index as a Novel Sonographic Tool to Predict High Risk Pregnancy (BFiORS Trial)

Sponsor

Assiut University

Status

UNKNOWN

Phase

Not Applicable

Condition raw

Gestational Diabetes, Pre-Eclampsia, Labour Dystocia

Condition normalized

Gestational Diabetes, Pre-Eclampsia, Labour Dystocia

Modality raw

RNA therapy

Modality normalized

RNA therapy

Target raw

Body Fat Index (BFI) as a predictive tool for gestational diabetes mellitus (GDM) and other pregnancy-related complications.

Target normalized

Body Fat Index (BFI) as a predictive tool for gestational diabetes mellitus (GDM) and other pregnancy-related complications.

Interventions

ultrasound

Public preview

Source record

The BFiORS Trial, sponsored by Assiut University, aims to validate the Body Fat Index (BFI) as a novel sonographic tool for predicting high-risk pregnancies, specifically focusing on gestational diabetes mellitus (GDM) and pre-eclampsia. Given the increasing prevalence of obesity among reproductive-aged women and its associated risks, this trial addresses a significant unmet need in obstetric care. The potential for BFI to serve as a cost-effective, non-invasive screening method could position it favorably in the maternal health market, particularly as healthcare systems seek to improve outcomes while managing costs. The trial's collaboration with reputable institutions such as Baylor College of Medicine enhances its credibility and may facilitate future partnerships or commercialization opportunities. However, the overall status of the trial is currently listed as 'Not Yet Recruiting,' which may delay market entry and impact investor interest.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account

Create a free account first, then unlock a single report, buy credits or subscribe.